HeeJin Cheon

HeeJin Cheon

Auto-generated profile, based on publicly available information

HeeJin Cheon

Department of Medicine and University of Virginia Cancer Center, Division of Hematology & Oncology, University of Virginia School of Medicine, Charlottesville, VA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2022 in Blood
Verified
Journal Article
Open access
PDF file
HCHeeJin Cheon
HeeJin Cheon
JXJeffrey C. Xing
Jeffrey C. Xing
KMKatharine B. Moosic
Katharine B. Moosic
JUJohnson Ung
Johnson Ung
VCVivian W. Chan
Vivian W. Chan
TLThomas P. Loughran
Thomas P. Loughran
Large granular lymphocyte (LGL) leukemia comprises a group of rare lymphoproliferative disorders whose molecular landscape is incompletely defined. We leveraged paired whole-exome and transcriptome sequencing in the largest LGL leukemia cohort to date, which included 105 patients (93 T-cell receptor αβ [TCRαβ] T-LGL and 12 TCRγδ T-LGL). Seventy-six mutations were observed in 3 or more patients in the cohort, and out of those, STAT3, KMT2D, PIK3R1, TTN, EYS, and SULF1 mutations were shared between both subtypes. We identified ARHGAP25, ABCC9, PCDHA11, SULF1, SLC6A15, DDX59, DNMT3A, FAS, KDM6A, KMT2D, PIK3R1, STAT3, STAT5B, TET2, and TNFAIP3 as recurrently mutated putative drivers using an unbiased driver analysis approach leveraging our whole-exome cohort. Hotspot mutations in STAT3, PIK3R1, and FAS were detected, whereas truncating mutations in epigenetic modifying enzymes such as KMT2D and TET2 were observed. Moreover, STAT3 mutations co-occurred with mutations in chromatin and epigenetic modifying genes, especially KMT2D and SETD1B (P < .01 and P < .05, respectively). STAT3 was mutated in 50.5% of the patients. Most common Y640F STAT3 mutation was associated with lower absolute neutrophil count values, and N647I mutation was associated with lower hemoglobin values. Somatic activating mutations (Q160P, D170Y, L287F) in the STAT3 coiled-coil domain were characterized. STAT3-mutant patients exhibited increased mutational burden and enrichment of a mutational signature associated with increased spontaneous deamination of 5-methylcytosine. Finally, gene expression analysis revealed enrichment of interferon-γ signaling and decreased phosphatidylinositol 3-kinase–Akt signaling for STAT3-mutant patients. These findings highlight the clinical and molecular heterogeneity of this rare disorder.

30 March 2021 in Blood
Verified
Journal Article
Open access
PDF file
TOThomas L. Olson
Thomas L. Olson
HCHeeJin Cheon
HeeJin Cheon
JXJeffrey C. Xing
Jeffrey C. Xing
KOKristine C. Olson
Kristine C. Olson
UPUmadevi Paila
Umadevi Paila
TLThomas P. Loughran
Thomas P. Loughran
Chronic natural killer large granular lymphocyte (NK-LGL) leukemia, also referred to as chronic lymphoproliferative disorder of NK cells, is a rare disorder defined by prolonged expansion of clonal NK cells. Similar prevalence of STAT3 mutations in chronic T-LGL and NK-LGL leukemia is suggestive of common pathogenesis. We undertook whole-genome sequencing to identify mutations unique to NK-LGL leukemia. The results were analyzed to develop a resequencing panel that was applied to 58 patients. Phosphatidylinositol 3-kinase pathway gene mutations (PIK3CD/PIK3AP1) and TNFAIP3 mutations were seen in 5% and 10% of patients, respectively. TET2 was exceptional in that mutations were present in 16 (28%) of 58 patient samples, with evidence that TET2 mutations can be dominant and exclusive to the NK compartment. Reduced-representation bisulfite sequencing revealed that methylation patterns were significantly altered in TET2 mutant samples. The promoter of TET2 and that of PTPRD, a negative regulator of STAT3, were found to be methylated in additional cohort samples, largely confined to the TET2 mutant group. Mutations in STAT3 were observed in 19 (33%) of 58 patient samples, 7 of which had concurrent TET2 mutations. Thrombocytopenia and resistance to immunosuppressive agents were uniquely observed in those patients with only TET2 mutation (Games-Howell post hoc test, P = .0074; Fisher’s exact test, P = .00466). Patients with STAT3 mutation, inclusive of those with TET2 comutation, had lower hematocrit, hemoglobin, and absolute neutrophil count compared with STAT3 wild-type patients (Welch’s t test, P ≤ .015). We present the discovery of TET2 mutations in chronic NK-LGL leukemia and evidence that it identifies a unique molecular subtype.

1 April 2020 in Current Hematologic Malignancy Reports
Verified
Journal Article
Closed access
PDF file
HCHeeJin Cheon
HeeJin Cheon
KDKarolina H. Dziewulska
Karolina H. Dziewulska
KMKatharine B. Moosic
Katharine B. Moosic
KOKristine C. Olson
Kristine C. Olson
AGAlejandro A. Gru
Alejandro A. Gru
TLThomas P. Loughran
Thomas P. Loughran

2 March 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
FLFrancis R. LeBlanc
Francis R. LeBlanc
JPJennifer M. Pearson
Jennifer M. Pearson
STSu‐Fern Tan
Su‐Fern Tan
HCHeeJin Cheon
HeeJin Cheon
JXJeffrey C. Xing
Jeffrey C. Xing
TLThomas P. Loughran
Thomas P. Loughran

2 March 2023 in Blood
Verified
Journal Article
Open access
PDF file
GBGregorio Barilà
Gregorio Barilà
AGAngela Grassi
Angela Grassi
HCHeeJin Cheon
HeeJin Cheon
ATAntonella Teramo
Antonella Teramo
GCGiulia Calabretto
Giulia Calabretto
Renato ZambelloRenato Zambello
Renato Zambello
Tγδ large granular lymphocyte leukemia (LGLL) is a rare variant of T-cell LGLL (T-LGLL) that has been less investigated as compared with the more frequent Tαβ LGLL, particularly in terms of frequency of STAT3 and STAT5b mutations. In this study, we characterized the clinical and biological features of 137 patients affected by Tγδ LGLL; data were retrospectively collected from 1997 to 2020 at 8 referral centers. Neutropenia and anemia were the most relevant clinical features, being present in 54.2% and 49.6% of cases, respectively, including severe neutropenia and anemia in ∼20% of cases each. Among the various treatments, cyclosporine A was shown to provide the best response rates. DNA samples of 97 and 94 cases were available for STAT3 and STAT5b mutation analysis, with 38.1% and 4.2% of cases being mutated, respectively. Clinical and biological features of our series of Tγδ cases were also compared with a recently published Tαβ cohort including 129 cases. Though no differences in STAT3 and STAT5b mutational frequency were found, Tγδ cases more frequently presented with neutropenia (P = .0161), anemia (P < .0001), severe anemia (P = .0065), and thrombocytopenia (P = .0187). Moreover, Vδ2− cases displayed higher frequency of symptomatic disease. Overall, Tγδ cases displayed reduced survival with respect to Tαβ cases (P = .0017). Although there was no difference in STAT3 mutation frequency, our results showed that Tγδ LGLL represents a subset of T-LGLL characterized by more frequent symptoms and reduced survival as compared with Tαβ LGLL.

11 July 2020 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
WTWanhu Tang
Wanhu Tang
HWHongshan Wang
Hongshan Wang
RTRuxiao Tian
Ruxiao Tian
SSSun Saret
Sun Saret
HCHeeJin Cheon
HeeJin Cheon
USUlrich Siebenlist
Ulrich Siebenlist